These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33914158)

  • 1. Prospective trial of treat-and-extend regimen with aflibercept for branch retinal vein occlusion: 1-year results of the PLATON trial.
    Park DG; Jeong WJ; Park JM; Kim JY; Ji YS; Sagong M
    Graefes Arch Clin Exp Ophthalmol; 2021 Oct; 259(10):2879-2886. PubMed ID: 33914158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
    Pichi F; Elbarky AM; Elhamaky TR
    Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.
    Korobelnik JF; Holz FG; Roider J; Ogura Y; Simader C; Schmidt-Erfurth U; Lorenz K; Honda M; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R;
    Ophthalmology; 2014 Jan; 121(1):202-208. PubMed ID: 24084497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A treat and extend protocol with Aflibercept for cystoid macular oedema secondary to central retinal vein occlusion - an 18-month prospective cohort study.
    O'Day R; Ali N; Lim LL; Sandhu S; Chau T; Wickremasinghe S
    BMC Ophthalmol; 2020 Feb; 20(1):69. PubMed ID: 32093666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
    Clark WL; Boyer DS; Heier JS; Brown DM; Haller JA; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Campochiaro PA
    Ophthalmology; 2016 Feb; 123(2):330-336. PubMed ID: 26522708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of aflibercept on persistent macular edema secondary to central retinal vein occlusion.
    Kaya F; Kocak I; Aydin A; Baybora H; Koc H; Karabela Y
    J Fr Ophtalmol; 2018 Nov; 41(9):809-813. PubMed ID: 30361176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.
    Campochiaro PA; Clark WL; Boyer DS; Heier JS; Brown DM; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Haller JA
    Ophthalmology; 2015 Mar; 122(3):538-44. PubMed ID: 25315663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study.
    Korobelnik JF; Larsen M; Eter N; Bailey C; Wolf S; Schmelter T; Allmeier H; Chaudhary V
    Am J Ophthalmol; 2021 Jul; 227():106-115. PubMed ID: 33556381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
    Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA
    Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Navigated laser and aflibercept versus aflibercept monotherapy in treatment-naïve branch retinal vein occlusion: A 12-month randomized trial.
    Frederiksen KH; Vestergaard JP; Pedersen FN; Vergmann AS; Sørensen TL; Laugesen CS; Kawasaki R; Peto T; Grauslund J
    Acta Ophthalmol; 2022 Nov; 100(7):e1503-e1509. PubMed ID: 35611568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
    Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
    Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial.
    Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Altaweel M; Berinstein DM;
    JAMA Ophthalmol; 2018 Apr; 136(4):337-345. PubMed ID: 29476687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year outcomes of the treat-and-extend regimen using aflibercept for the treatment of diabetic macular edema.
    Sheu SJ; Yang CH; Lai CC; Wu PC; Chen SJ
    J Chin Med Assoc; 2022 Feb; 85(2):246-251. PubMed ID: 34974510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treat-and-extend therapy with aflibercept for diabetic macular edema: a prospective clinical trial.
    Hirano T; Toriyama Y; Takamura Y; Sugimoto M; Nagaoka T; Sugiura Y; Okamoto F; Saito M; Noda K; Yoshida S; Ishibazawa A; Sawada O; Murata T
    Jpn J Ophthalmol; 2021 May; 65(3):354-362. PubMed ID: 33559843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies.
    Feltgen N; Ogura Y; Boscia F; Holz FG; Korobelnik JF; Brown DM; Heier JS; Stemper B; Rittenhouse KD; Asmus F; Ahlers C; Vitti R; Saroj N; Mitchell P
    Ophthalmol Retina; 2019 Jul; 3(7):553-560. PubMed ID: 31277796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series.
    Braimah IZ; Agyabeng K; Amoaku WM
    Int Ophthalmol; 2021 Jul; 41(7):2445-2453. PubMed ID: 33782846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
    Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
    Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
    Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
    Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous intravitreal dexamethasone and aflibercept for refractory macular edema secondary to retinal vein occlusion.
    Giuffrè C; Cicinelli MV; Marchese A; Coppola M; Parodi MB; Bandello F
    Graefes Arch Clin Exp Ophthalmol; 2020 Apr; 258(4):787-793. PubMed ID: 31897703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.